Shanghai Junshi Biosciences : SUPPLEMENTAL NOTICE OF THE 2020 FIRST EXTRAORDINARY GENERAL MEETING

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海 君實生物醫 藥科技股份 有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

SUPPLEMENTAL NOTICE OF THE 2020 FIRST EXTRAORDINARY

GENERAL MEETING

Reference is made to the notice of the 2020 first extraordinary general meeting ("EGM") of Shanghai Junshi Biosciences Co., Ltd.* (the "Company") dated 21 November 2019 (the "Notice"), the circular dated 3 December 2019 (the "Circular") and the announcement dated 13 December 2019 with regard to the postponement of the EGM and the corresponding arrangements (the "Postponement Announcement"). This supplemental notice should be read in conjunction with the Notice.

As stated in the Postponement Announcement, the EGM will be postponed to be held at Jumeirah Himalayas Hotel Shanghai, No. 1108 Mei Hua Road, Pudong New District, Shanghai, the People's Republic of China on Monday, 3 February 2020 at 10:30 a.m. (the "Postponed EGM").

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that in addition to the resolutions contained in the Notice, the following resolution will be considered, and if thought fit, approved by the shareholders of the Company at the Postponed EGM:

SUPPLEMENTAL ORDINARY RESOLUTION

6. To consider and approve the ratification of related party transaction in 2018.

By Order of the Board

Shanghai Junshi Biosciences Co., Ltd.*

Mr. Xiong Jun

Chairman

Shanghai, PRC, 20 December 2019

- 1 -

Notes:

1. Due to the postponement of the EGM, the period of closure of the register of members of H shares of the Company will be changed from the original period from Saturday, 7 December 2019 to Monday, 6 January 2020 (both days inclusive) to the new period of Saturday, 4 January 2020 to Monday, 3 February 2020 (both days inclusive) during which period no transfer of H shares of the Company will be registered, in order to determine the entitlements of the shareholders of the Company to attend and vote at the Postponed EGM to be held on Monday, 3 February 2020. In order to be eligible to attend and vote at the EGM, all transfers of H Shares accompanied by the relevant share certificates and transfer forms must be lodged with the Company's H Share registrar, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong (for holders of H shares) before 4:30 p.m. on Friday, 3 January 2020, being the last share registration date.
2. A supplemental proxy form (the "Supplemental Proxy Form") containing the resolution mentioned above is enclosed. The proxy form issued by the Company on 21 November 2019 (the "Original Proxy Form") will remain valid and effective to the fullest extent applicable if correctly completed and lodged with the H share registrar of the Company.
3. Shareholders who intend to attend the meeting by proxy should complete the Original Proxy Form and/or Supplemental Proxy Form. For holders of H shares, the Original Proxy Form and/or Supplemental Proxy Form should be returned to the Company's H Share registrar, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, in person or by post as soon as possible not less than 24 hours before the time fixed for holding the meeting or any adjournment thereof. Completion and return of the Original Proxy Form and/or Supplemental Proxy Form will not preclude you from attending the meeting and any adjournment thereof and voting in person. In such event, the form of proxy shall be deemed to be revoked.
4. Shareholders who intend to attend the meeting in person or by proxy should return the revised reply slip (for holders of H shares) to the Company's H share registrar, Tricor Investor Services Limited on or before Tuesday, 14 January 2020.
5. Further details of the resolution will be included in the supplemental circular to be despatched to shareholders

by	the Company. Please also refer to the overseas regulatory announcements of the Company dated
13	December 2019.

1. Save for the inclusion of the newly proposed resolution and the postponement, there are no changes to the resolutions set out in the Notice. Please refer to the Notice and the Circular for the other resolutions to be passed at the EGM and other relevant matters. Please also refer to the original notice of EGM.
2. Since the Original Proxy Form does not contain the proposed additional resolution as set out in this supplemental notice, the Supplemental Proxy Form has been prepared and is enclosed with this supplemental notice. The Supplemental Proxy Form for use at the EGM is also published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (www.junshipharma.com).
3. This supplemental notice of meeting is despatched to the holders of H Shares only. The supplemental notice of meeting to the holders of Domestic Shares is separately published on the website of the National Equities Exchanges and Quotations (http://www.neeq.com.cn).

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.

• For identification purpose only.

- 2 -